Taro Pharmaceutical Industries Ltd.  

(Public, NYSE:TARO)   Watch this stock  
Find more results for Taro Pharmaceutical Industries Ltd
0.00 (0.00%)
Real-time:   4:02PM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 138.49 - 138.49
52 week 122.99 - 157.99
Open 138.49
Vol / Avg. 0.00/275,468.00
Mkt cap 5.64B
P/E 10.94
Div/yield     -
EPS 12.63
Shares 42.77M
Beta 0.87
Inst. own 15%
Aug 4, 2016
Q1 2017 Taro Pharmaceutical Industries Ltd Earnings Release (Estimated) Add to calendar
May 27, 2016
Q4 2016 Taro Pharmaceutical Industries Ltd Earnings Call - Webcast
May 26, 2016
Q4 2016 Taro Pharmaceutical Industries Ltd Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2016
Net profit margin 43.40% 56.96%
Operating margin 68.55% 64.63%
EBITD margin - 66.51%
Return on average assets 21.67% 27.59%
Return on average equity 24.93% 32.38%
Employees 1,407 -
CDP Score - -


14 Hakitor Street, Haifa Bay P.O. Box 10347
HAIFA, 26110
+972-4-8475700 (Phone)
+972-4-8727165 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company develops, manufactures and markets prescription (Rx) and over-the-counter (OTC) pharmaceutical products, primarily in the United States, Canada and Israel. Taro also develops and manufactures active pharmaceutical ingredients (APIs), primarily for use in its finished dosage form products. The Company's primary areas of focus include semi-solids formulations, such as creams and ointments, and other dosage forms, such as liquids, capsules and tablets, primarily in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. Taro's owned product brands include Rokacet, Topicort, Etopan, Lustra and Ovide. Its other generic products include acetazolamide, amiodarone hydrochloride, ammonium lactate, calcipotriene, carbamazepine, cetirizine hydrochloride, ciclopirox olamine, clindamycin, clobetasol propionate and clomipramine hydrochloride.

Officers and directors

Dilip Shantilal Shanghvi Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Kalyanasundaram Subramanian Chief Executive Officer, Director
Age: 62
Bio & Compensation  - Reuters
Michael H. Kalb CPA Group Chief Financial Officer, Chief Accounting Officer
Age: 45
Bio & Compensation  - Reuters
Stephen Manzano Esq. Group Vice President, General Counsel, Secretary, Corporate Compliance
Age: 51
Bio & Compensation  - Reuters
Itamar Karsenti Vice President - Head of Operations, Haifa
Age: 44
Bio & Compensation  - Reuters
Chantal LeBlanc Vice President - Global Quality
Age: 53
Bio & Compensation  - Reuters
Daryl LeSueur Vice President - Head of Operations, Brampton
Age: 53
Bio & Compensation  - Reuters
Michael Perfetto Group Vice President and Chief Commercial Officer of the Generic Rx Business
Age: 55
Bio & Compensation  - Reuters
Michael Teiler Group Vice President - Portfolio Management
Age: 53
Bio & Compensation  - Reuters
Avi Avramoff Ph.D. Global Vice President - Research & Development
Age: 51
Bio & Compensation  - Reuters